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Identification of a human neonatal
immune-metabolic network associated
with bacterial infection
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Understanding how human neonates respond to infection remains incomplete. Here,
a system-level investigation of neonatal systemic responses to infection shows a surprisingly
strong but unbalanced homeostatic immune response; developing an elevated set-point of
myeloid regulatory signalling and sugar-lipid metabolism with concomitant inhibition of
lymphoid responses. Innate immune-negative feedback opposes innate immune activation
while suppression of T-cell co-stimulation is coincident with selective upregulation of CD85
co-inhibitory pathways. By deriving modules of co-expressed RNAs, we identify a limited set
of networks associated with bacterial infection that exhibit high levels of inter-patient
variability. Whereas, by integrating immune and metabolic pathways, we infer a patient-
invariant 52-gene-classifier that predicts bacterial infection with high accuracy using a new
independent patient population. This is further shown to have predictive value in identifying
infection in suspected cases with blood culture-negative tests. Our results lay the foundation
for future translation of host pathways in advancing diagnostic, prognostic and therapeutic
strategies for neonatal sepsis.
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D
espite advances in neonatal care, infection remains a
leading cause of morbidity and mortality in neonates
worldwide. Although progress towards survival of
children under the age of 5 years has been made as one of the
Millennium Development Goals, neonatal morbidity and
mortality remain a major issue in resource-rich and -poor
settings1. Of 7.6 million deaths in children younger than 5 years
in 2010, 64.0% (4.879 million) were attributable to infectious
causes and 40.3% (3.072 million) occurred in neonates1. Up to
65% of extremely low-birth-weight infants develop presumed
sepsis in the neonatal period2. Accordingly, there is a low
threshold for clinical suspicion of infection in neonates,
particularly as presentation varies greatly from very subtle signs
to catastrophic collapse. Empirical antibiotics are widely used
because of the lack of reliably sensitive tests and the potential
life-threatening consequences of delayed treatment of infection.
This exposes many infants without infection to broad-spectrum
antibiotics.
Clinical investigation of neonates is problematical and our
understanding of neonatal sepsis is hampered by a lack of
appropriate animal models and species-specific differences in
response to infection. Neonates are more susceptible to infection
than older individuals, however, neonatal immunity is not well
characterized3. Moreover, host responses are known to play a
significant role in the pathophysiology of sepsis; yet our
understanding of how humans respond at the systemic pathway
level to infection in early life is not known.
Systems investigations using genomics, in particular, are
increasingly used to examine host–pathogen interactions in an
unbiased manner4–6. Changes in host gene expression may occur
pre-symptomatically in response to infection in any part of the
body, with the continuous interaction between blood and tissue
allowing blood cells to act as internal biosensors for the
changes6,7. Studies have examined transcription profiles of
blood from adults and children with infection, but data from
infected neonates are lacking4,8–12. However, a limited number of
host markers at the protein level have been investigated in
neonates13–17. It is likely that neonatal transcriptional responses
differ from other age groups because neonates are
developmentally immature and may be encountering infection
for the first time.
Towards applying a systematic system-level investigation, we
previously assessed variability and statistical power of measuring
neonatal whole blood RNA18. These studies lent support to the
notion of using whole blood rather than peripheral blood
mononuclear cell profiling for a more full picture of the host
response. Furthermore, before extensive clinical investigations we
developed a high-performance computing model for host RNA
classification. These simulations demonstrated that as few as 24
whole blood RNA markers (comprising biological pathways)
would be sufficient for predicting infection19. These studies and
those published by others in older infected individuals support
the approach of using host whole blood RNA to systematically
identify the pathway biology underlying the pathogenesis of
neonatal infection.
In this study, we characterize the pathway biology underlying
neonatal sepsis at the first clinical signs of infection. We derive
and validate a panel of pathway biomarkers that are further
clinically evaluated for potential future translation in stratifying
neonatal infection.
Results
Vigorous systemic host RNA perturbation in neonatal
infection. First, we assessed the magnitude and extent of varia-
bility of gene expression using the training set and one virally
infected case. In these analyses, 23,342 probes gave detectable
signal for one or more samples. Of these, 10,206 showed a
coefficient of variation of 40.1 across all 63 samples. A principal
components analysis of patient samples based on these 10,206
probes and agglomerative unsupervised clustering of normalized
unfiltered data revealed a separation into control and infected
groups (Fig. 1a and Supplementary Fig. 1). The single exception
was the virally infected case and was excluded from later analyses.
Statistical testing further underscored the large-scale demarca-
tion of response, revealing 8,242 significantly differentially
expressed probes (adj.Pr0.01) with adjusted P values as low
as 10 23. By applying statistical and quantitative cutoffs
(adj.Pr0  01, absolute fold change Z2) this was reduced to
824 and accordingly represents a global signature of infection for
a naı̈ve neonatal immune system. Euclidean distance-based
clustering of the 824 differentially expressed probes (Fig. 1b
and Supplementary Data set 1, worksheet 1) revealed upregulated
(yellow) and downregulated (blue) genes in infection, demarcated
by three groups: group 1 representing downregulated; group 2
those upregulated; whereas group 3 showing no clear separation
between infected and controls. Many of the 118 probes in group 3
encode functions related to blood development (Supplementary
Fig. 2i,j) and were excluded from subsequent analyses.
Pathway biology responses to infection. To identify the most
highly active set of pathways associated with infection, we applied
additional filtering to groups 1 and 2 using more stringent cutoffs
(adj.Pr10 5, fold change Z4). Analysis of the resulting
52 genes revealed sub-networks (termed ‘dual-network’), for
upregulated and downregulated expression. The dual-network
shows a uniformly clear signal separation into activated (yellow)
and suppressed (blue) genes in infected cases (Fig. 2a) and con-
sists of three functional pathway classes of innate and adaptive
immunity and unexpectedly metabolic pathways for sugar and
lipid metabolism (Fig. 2b–e and Supplementary Fig. 3). Overall,
these results show a vigorous systemic host RNA network
perturbation upon bacterial infection.
Immune signalling pathway. To interrogate signalling pathways
in groups 1 and 2, we performed hypergeometric tests using
the Ingenuity Pathways Analysis (IPA) database (http://www.
ingenuity.com), developing eight highly connected networks of
functionally related genes (Supplementary Fig. 2a–h). Group 1
mapped to antigen processing and presentation via major histo-
compatibility complex II, lymphocyte differentiation, T-cell acti-
vation and T-cell receptor (TCR) signalling. Group 2 mapped to
innate immune processes including Toll-like receptor (TLR),
chemokine, interleukin (IL)-6, IL-1b and Janus kinase-Signal
Transducer and Activator of Transcription (JAK-STAT) signal-
ling, platelet activation and apoptosis. It is noteworthy that
interferon (IFN)-g, although expressed in all patient samples, is
not differentially activated (Fig. 3a,b). Although this is consistent
with the reduction in levels of expression of genes of the adaptive
immune system (Fig. 3a), the IFNg regulated gene CXCL10,
showing a good correlation with STAT1 in infected cases (r¼ 0.8)
but not in controls (r¼ 0.3; Supplementary Fig. 4).
IPA analysis of the 52-gene dual-network confirmed the three
pathways of innate, adaptive and metabolic. The upregulated sub-
network forms a myeloid innate immune and metabolic signature
anchored around matrix metallopeptidase 9 (MMP9) and
lipocalin 2 (LCN2) associated with macrophage activation and
lipid metabolism (Fig. 2b; Supplementary Fig. 3a). Other
metabolic genes include the free fatty acid receptor 2 (FFAR2/
GPR43) that links short chain fatty acids, neutrophils and gut–
microbiota interactions as well as glycolytic and energy
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metabolism (Fig. 2c; Supplementary Fig. 3a). The downregulated
pathway comprises lymphoid markers of adaptive immunity
centred on the TCR/CD3 complex and associated TCR signalling
pathways (Fig. 2d; Supplementary Fig. 3b). Taken together, this
analysis provides, for the first time, a link between metabolic and
inflammatory processes in neonatal sepsis (Fig. 2e).
Immune inhibitory signalling. Notably, upregulation of inhibi-
tory signalling pathways is observed. The decoy receptor for IL-
1b (IL1R2) and the IL-1 receptor antagonist (IL1RN; Fig. 3b)
systemically counteract the inflammatory response, and is con-
current with a broad cell intrinsic inhibitory response. Cell
intrinsic repressors include A20, IkBa, TOLLIP, TRAFD1,
TRAIL-R3 (TNFRSF10C), IRAK-M, SOCS1 and SOCS3 that
counter regulate the NF-kB, TLR, MYD88, IRAK and JAK-STAT
signalling pathways, respectively (Supplementary Fig. 5). These
counter regulatory pathways affect the set-point in immune-
homeostatic control (defined here as the level at which the innate
immune system activates the adaptive response) that is governed
by the net balance between inhibitory and stimulatory responses.
Accordingly, although a significant number of infected infants
show elevated CD163 macrophage-activation marker expression
(adj.Pr10 6), they also exhibit increased co-inhibitory ligands
such as PD-L1 (CD274) that impedes T-cell proliferation and
cytokine production. Moreover, genes associated with myeloid-
derived suppressor cells are elevated (CD11B, CD97) including
increased ARG1 that marks a potent anti-inflammatory
Sample relations based on 10,206 genes with CV > 0.1
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Figure 1 | Hierarchical clustering of infected and control patient samples. (a) Results from unsupervised analysis of normalized data before statistical
testing. At this stage, the condition of whether the samples were infected or not had not been included in the analysis. Control, blue; infected, red.
(b) Heat map showing hierarchical clustering of infant samples based on the 824 probes that were statistically differentially expressed between infected
and control groups (using eBayes with Benjamini-Hochberg correction adj.Pr0.01, absolute fold change Z2). Hierarchical clustering was based on
Euclidean distance. Three clusters of genes are labelled (1–3). Group 3 genes (highlighted with an orange box) were excluded from the further analysis
for derivation of a classifier of neonatal bacterial infection because of no clear separation between infected and controls. Control, blue; infected, red.
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Figure 2 | 52-Gene dual-network classifier of neonatal bacterial infection comprised of innate, metabolic and adaptive immune pathways.
(a) Line graph of per gene normalized expression values using the 52-gene dual-network classifier of neonatal bacterial infection with sample order
determined using hierarchical clustering based on Euclidean distance. Line graphs of per gene normalized expression values using genes associated
with (b) innate immune, (c) metabolic, (d) adaptive immune and (e) combination of all three pathways present in the 52-gene dual-network classifier
of neonatal bacterial infection. Control, blue; bacterial infected, red.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5649
4 NATURE COMMUNICATIONS | 5:4649 | DOI: 10.1038/ncomms5649 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
phenotype (Fig. 3c). In relation to elevated ARG1, the CD71
erythroid cell marker was also upregulated (Supplementary Fig. 5)
and in neonates contributes towards the suppression of immune
cell activation20. A corollary of the stimulatory and inhibitory
signalling pathways is their likely impact on functional changes in
immune cell compartments.
Changes in immune cell compartment. To investigate cellular
compartments, we used markers of specific blood cell lineages21
(Supplementary Data set 2) to model cell-type-specific modules of
RNA expression. An increased level of myeloid cells, especially
monocytes and neutrophils, is inferred in infected samples
(Fig. 3e,f; Table 1), which was validated by a significantly
increased neutrophil cell count (Fig. 3d). Conversely, expression
modules for lymphoid cells, particularly B and T cells were lower
(Fig. 3e,f). A significant difference is not detected for either
dendritic or natural killer cells (Table 1). We conclude that
in sepsis the heightened innate immune cellular response is
driven by monocytes/macrophages and neutrophils and is
counter-balanced by inhibitory pathways resulting in a net
suppression of the adaptive immune arm, especially associated
with the T-cell compartment.
Regulatory nodes. To gain insight into the underlying regulatory
nodes, we used the InnateDB resource22 filtered for a high-
confidence manually annotated data set of approximately 2,500
human molecular interactions. Analysis of direct interactions
between group 2 genes (Fig. 4a left) revealed those genes
(represented as ‘nodes’ in the network) that are highly connected
through direct physical or biochemical interactions (termed
‘hubs’) or which have many network shortest paths passing
through them (termed ‘bottlenecks’) that mark potential key
regulatory points in the network. The 20 major hubs were
identified, of which the top four included immune regulatory
factors STAT1, STAT3 and C/EBP-B, and the TNFR1 receptor
(Fig. 4a middle). The level of innate immune response triggering
IL
10
IF
N
A
7
IF
N
A
8
IF
N
A
10
IF
N
A
R
1
IF
N
A
R
2
IF
N
K
IF
N
G
IF
N
G
R
2
IL
10
R
A
IL
10
R
B
IL
12
R
B
1
IL
12
R
B
2
H
LA
–A
H
LA
–B
H
LA
–C
H
LA
–E
H
LA
–F
H
LA
–G
H
LA
–H
H
LA
–D
M
A
H
LA
–D
M
B
H
LA
–D
O
A
H
LA
–D
O
B
H
LA
–D
P
A
1
H
LA
–D
P
B
1
H
LA
–D
R
A
H
LA
–D
R
B
1
H
LA
–D
R
B
3
H
LA
–D
R
B
4
H
LA
–D
R
B
5
H
LA
–D
R
B
6
P
S
M
B
8
P
S
M
B
9
P
S
M
B
10
P
S
M
E
1
P
S
M
E
2
P
S
M
E
3
T
A
P
1
T
A
P
2
F
ol
d 
ch
an
ge
–2
–3
–4
–5
+/–1
2
Lymphoid cell probes
0
–3 –1 0 1 3
3
6
9
12
15
Myeloid cell probes
0
–3 –1 0 1 3
3
6
9
12
15
A
R
G
1
C
D
11
B
/IT
G
A
M
C
D
11
C
/IT
G
A
X
C
D
97
/G
R
1
F
ol
d 
ch
an
ge
+/–1
3
2
4
P
=
6.
68
×1
0–
8
P
=
3.
54
×1
0–
15
P
=
4.
67
×1
0–
12
P
=
7.
44
×1
0–
11
10
5
+/–1
F
ol
d 
ch
an
ge
IL
1A
IL
1R
1
IL
1R
A
P
IL
1R
L1
IL
1R
2
IL
1R
N
IL
1B
IL
18
M
Y
D
88
T
G
IF
1
T
LR
1
T
LR
2
T
LR
4
T
LR
5
T
LR
6
T
LR
7
T
LR
8
T
LR
9
T
LR
10
T
N
F
T
N
F
S
F
13
T
N
F
S
F
13
B
/B
A
F
F
T
N
IP
1
T cell probes
–1 0 1–3 3
B cell probes
0
3
6
9
12
15
–1 0 1–3 3
NK cell probes
–1 0 1–3 3
Neutrophil probes
–1 0 1–3 3
Dendritic cell probes
–1 0 1–3 3
Monocyte probes
–1 0 1–3 3
In
fe
ct
ed
C
on
tr
ol
N
eu
tr
op
hi
l c
el
l c
ou
nt
(×
10
6  
m
l–
1 )
0
2
4
6
8
10*
–l
og
10
 A
dj
.P
log2fc log2fc log2fc log2fc log2fc log2fc
log2fc
log2fc
–l
og
10
A
dj
.P
–l
og
10
 A
dj
.P
Figure 3 | Differential adaptive and innate immune responses to neonatal infection. (a) Fold change in expression of adaptive immune response genes
following neonatal infection. (b) Fold change in expression of innate immune response genes following neonatal infection. (c) Fold change in expression of
genes associated with myeloid-derived suppressor cells following neonatal infection. Significance is indicated by adjusted P-values for fold change of each
probe (using eBayes with Benjamini-Hochberg correction). (d) Neutrophil cell counts from control and infected patients. Neutrophil cell counts were
examined in control (n¼ 12) and infected (n¼ 28) patients and are expressed as numbers  106 cells per ml of blood with the plot presenting median
values±median absolute deviation. Significance testing between conditions was performed using a one-way analysis of variance test, * indicates
significance at Po0.0005. (e,f) Cell type enrichment analysis. Volcano plots of expression profiles associated with particular blood cell types and classes.
Gene lists used to perform this analysis are detailed in Supplementary Data set 2. Log2 fold change is on the x axis and –log2 adjusted P value on the y axis
(using eBayes with Benjamini–Hochberg correction). (e) Expression profiles for lymphoid and myeloid cells. (f) Expression profiles for B, T, NK cells,
neutrophils, monocytes and dendritic cells. Significantly differentially expressed probes (with adj.Pr0.01) are shown in red.
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Table 1 | Cell type enrichment analysis.
Cell type Annotated probes Expected probes Found Change on infection v2 P-value
B cell 111 14 46 Down 3.61 1005
Dendritic cell 108 13 28 Unchanged 0.0191
Lymphoid 338 43 128 Down 8.03 10 11
Monocyte 106 13 36 Up 0.00102
Myeloid 429 55 192 Up 2.85 10 18
Neutrophil 49 6 29 Up 0.000101
NK cell 18 2 5 Unchanged 0.257
T cell 102 13 33 Down 0.00319
A summary of probe detection based on cell type-specific gene lists as detailed in Supplementary Data set 2 and whether expression for each cell type on encountering infection was seen to be
unchanged, higher (up) or lower (down).
TNFRF1 NFKBIA
CEBPB
STAT1STAT3
a
b c
Cell surface
Plasma membrane
Cytoplasm
Nucleus
Transcriptional regulation
Transcriptional regulation
Nucleus
Cytoplasm
Plasma membrane
Cell surface
Extracellular
Figure 4 | Networks of experimentally supported direct molecular interactions between genes differentially regulated in neonatal sepsis.
(a) Network relationships derived from InnateDB were visualized with Cytoscape. (Left) Network of direct molecular interactions between genes
upregulated in neonatal sepsis patients (shown in red), their encoded products and all other interacting molecules. Inclusion of non-differentially expressed
interacting partners (shown in grey) in this network allows potential identification of important regulatory nodes (genes/proteins) not evident from
microarray data alone (for example, constitutively expressed nodes/nodes expressed at a time point not sampled in the study). (Middle) The top five hub
nodes identified by Degree algorithm of cytoHubba plugin are labelled. Node sizes are defined by the node degree— the larger the node size the higher
the degree. Nodes encoded by upregulated genes are shown in red, the top 20 hubs identified by this analysis were STAT1, STAT3, NFKBIA, TNFRF1,
CEBPB, SPI1, LYN, BCL6, PRKCD, HCK, MYD88, HSPA1B, UBA1, CEBPD, JUNB, IRF7, TNFAIP3, CTNNA1, ETS2 and GNAI2. (Right) The top-scoring
upregulated sub-network identified by jActiveModules plugin. Nodes representing upregulated RNA signals are shown in red; non-differentially expressed
genes in grey. (b) Network of molecular interactions directly between genes upregulated in neonatal sepsis patients visualized with the Cerebral v.2 plugin.
Nodes encoded by upregulated genes are shown in red; non-differentially expressed interactions partners are not shown. (c) Network of molecular
interactions directly between genes downregulated in neonatal sepsis patients visualized with the Cerebral v.2 plugin. Nodes encoded by downregulated
genes are shown in green; non-differentially expressed interaction partners are not shown.
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reflects the set-point for homeostatic immune regulation, and the
activity of these nodes points to a heightened set point. The
network was further analysed to identify ‘active sub-networks’ via
the identification of high scoring sub-networks using a search
algorithm based on simulated annealing23. The top-ranked
upregulated sub-network (Fig. 4a right), consisted of 81 nodes
and 176 edges and was enriched in genes involved in Formation
of Platelet plug, Fc gamma R-mediated phagocytosis, Platelet
Activation, Hemostasis, Integrin signalling and chemokine
signalling pathways.
An investigation of the regulatory interactions directly between
nodes (Fig. 4b) showed a major connected component consisting
of proteins involved in TLR (TLR5, TLR8, MYD88, IRAK3) and
TNF signalling (among other pathways) leading to the transcrip-
tional activation of a range of genes via a panel of transcription
factors, including BCL6, CEBPB, CEBPD, ETS2, IRF7, JUNB,
SPI1, STAT1 and STAT3. Minor components in the network
consisted of genes involved in platelet activation (GNAI2, PPBP)
and chemokine/cytokine signalling (GNAI2, IL8RA, IL8RB,
PPBP) and involved in Fc-gamma R-mediated phagocytosis
(DNM2, FCGR1A, FCGR2A, HCK, LYN).
Next, we investigated interactions between downregulated
nodes and all their interaction partners. The top 20 hubs in the
downregulated network were identified and included the ETS1
transcription factor, several proteins involved in translation
(EIF3E, EIF4A2, RPLP1, TUT1), two involved in cell cycle
regulation (ATM, RBL2) and the cytokine receptor, IL7R. Many
of these nodes were also identified as network bottlenecks. The
top three differentially expressed sub-networks consisted of a
network enriched in genes involved in translation, the HNF4A
transcriptional module and a network enriched in components of
TCR signalling (Fig. 4c).
Taken together, we conclude that the overriding pathophysio-
logical signal associated with neonatal infection is one of the
increased innate immune metabolic responses with an unba-
lanced homeostatic regulation of adaptive immunity. The specific
and intense activation of innate immune signalling, moderated
via inhibitory pathways is consistent with the notion of an
elevated set point in neonates in comparison with adults for
guiding a suppressed adaptive immune response24.
Metabolic pathway biology and immune homeostasis.
Unexpectedly, we found marked transcriptional changes in
specific metabolic pathways, principally associated with glucose,
energy and cholesterol metabolism (Supplementary Fig. 5). For
cholesterol biosynthesis and homeostasis, we find significant
alterations in SQLE, IDI1, DHCR7, SCAP, INSIG2, NR1H2,
ABCA1, LDLR and LDLRAP1 (Supplementary Fig. 5). In the case
of the glycolysis pathway, three key regulatory nodes of the
pathway form part of the 52-gene dual-network (Fig. 2c). These
are increased levels of the glucose transporter GLUT3 (SLC2A3),
PFKFB3 (6-phophofructo-2-kinase) that activates the glycolytic
flux under hypoxic conditions and HK3 a hexokinase that
phosphorylates glucose to produce glucose-6-phosphate, the first
rate-limiting step in glucose metabolism; and is indicative of
changes in the tricarboxylic acid cycle. Another member of the
dual-network involved in regulating lipid and glucose metabolism
is lipocalin 2 (LCN2)25,26, which also plays a role in the innate
immune response to bacterial infection by sequestering iron27–30.
Other metabolic players of the dual-network include B4GALT5
that is responsible for synthesis of complex N-linked
oligosaccharides for glycoproteins and glycolipids; and GYG1
that forms an oligosaccharide primer substrate for glycogen
synthase. These metabolic processes are likely to be linked to the
innate immune response. In support, analysis of the promoters of
the metabolic sub-network identified 11 out of 13 genes
containing binding sites for the myeloid-specific transcription
factor PU.1 (SPI1), which is also part of the dual-network
(Supplementary Table 1).
A crucial contribution to coupling homeostasis of host
metabolism and the immune system is the microbial colonization
of the intestine at birth. Here homeostatic regulatory pathways
involve interactions between immune cells and metabolic
products (primarily small chain fatty acids such as butyrate) of
microbiota fermentation, which influences the set point for an
immune response. In this connection, the free fatty acid receptor
2 (FFAR2/GPR43) plays a key role in linking the metabolic
activity of the gut microbiota with body energy metabolism and
immune activity and is an immune metabolic node within the
dual-network. Systemically, FFAR2 is primarily expressed on
neutrophils and granulocytes and a positive correlation between
FFAR2 levels and the number of neutrophils in the control group
is observable (r¼ 0.7), but this correlation is lost in bacterial
infection cases (r¼ 0.2). This indicates that FFAR2 upregulation
in sepsis is not due to increased neutrophil numbers but is
suggestive of an immune-mediated upregulated response
(Fig. 5a). STAT3 is one of the key immune-regulated hubs in
sepsis (Fig. 4a middle) and the FFAR2 promoter has a predicted
STAT3-binding site (Fisher score 0.9). In agreement, we find
FFAR2 has a strong correlation with the levels of STAT3 in
neonatal sepsis patients (r¼ 0.8) but not in the controls (r¼ 0.3;
Fig. 5b). In contrast, correlation between FFAR2 levels and FCN1
in either controls (r¼ 0.1) or infected group (r¼ 0.1) is low
(Fig. 5c). M-ficolin (FCN1) encodes a collagen-type (C-type)
lectin protein secreted by macrophages that binds FFAR2 on
plasma membranes acting as part of the host innate immune
activation pathway. Thus, rather than the host factor FCN1,
microbial short-chain fatty acid metabolites derived from the gut
microbiota such as butyrate likely act as the cognate ligands for
FFAR2 on neutrophils, which functionally tunes the peripheral
immune system31,32. These results will require further
investigation but are consistent with the emerging view that the
metabolic activity of the neonatal microbiota may contribute to
control the systemic threshold of activation of innate and
adaptive immune cells.
The activity of immunosuppressive CD71þ erythroid cells has
been implicated in suppressing host defence against infection in
neonates20. Although expressed on a variety of blood cells, it is
upregulated in sepsis but in only a small number of cases
(Supplementary Fig. 5) and is insufficient alone to explain the
hypo-responsiveness of the adaptive arm.
Homeostatic co-signal regulatory control. The interaction
between myeloid antigen-presenting cells and lymphoid T cells,
serve as the immune control centre integrating homeostatic reg-
ulatory signals that govern the adaptive effector arm. Interaction
of antigen–HLA complexes in T-cell activation requires two
signals, TCR signalling and co-signal regulation. Moreover, naı̈ve
T cells are strongly dependent on co-signalling, which plays a
vital role in either promoting or inhibiting T-cell activation. For
the first TCR signal, expression of HLA class II is significantly
downregulated in our sepsis cases (Fig. 3a). For the co-signal,
CD80/CD86/CD28 interactions form the strongest co-
stimulatory pathway and CD28-deficient cells fail to proliferate.
In our neonatal sepsis cases, we find the differential gene
expression for this pathway is dramatically diminished as well as
expression levels of ICOS, CD27, LIGHT and CD2 (Fig. 5d).
Although there was a small number of infected cases that showed
increased TNFSF15, ICAM1, LFA-1 and 3 expression levels, the
notably marked downregulation of CD3, LIGHT and CD2 was
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indicative of a suppression of T-cell priming that plays a role in
the transition from quiescent to activated states (Fig. 5d and
Supplementary Fig. 5). In the case of co-inhibitory pathways, a
highly specific and selective differential gene expression response
was observed for the inhibitory receptor Ig-like transcripts
(CD85A, CD85D and CD85K)33–36 and potential dual co-
inhibitory and co-stimulatory CD85E and CD85F transcripts
(Fig. 5e). The increased expression of these receptors, in
particular CD85K, converts T cells into suppressive cells36.
Thus, examination of the complex co-signalling regulatory system
reveals a highly focused and selective response in neonatal sepsis.
Although these responses may be dynamically varied at the time
of sampling, they clearly show quite a remarkably restricted and
specific pattern. These negative regulatory pathways are
suggestive of a significant new mechanism in neonates for
contributing to suppression of the adaptive arm.
Heterogeneity of infection-specific network responses. We
anticipate that individuals will have different responses. To
examine this, we applied a data-driven approach for determining
networks of co-expressed RNAs that are exclusive to infected
infants. Modules were derived from the linear dependence of the
824 statistically significant gene probes and used a Markov
Cluster Algorithm implemented in the BioLayout tool37 for
revealing correlated probes among patient samples. This type of
analysis is highly subjective as clustering parameters are chosen
visually by discerning discrete clusters termed ‘cliques’ and these
will vary greatly in size and degree of connectivity dependent on
the parameter chosen. Nevertheless, this approach is useful for
exploring data-driven assignment of co-regulated genes for
infected cases. Figure 6a,b shows the developed modules of co-
expressed genes using parameter cutoffs of Pearson correlation
r¼ 0.78 and Markov Cluster Algorithm inflation value of 4 and
pre-inflation value of 3. In this analysis, 12 discernibly different
modules are associated with infection and post-hoc pathway
analysis shows each corresponding to a defined biological process
(Fig. 6b, Supplementary Fig. 6 and Supplementary Data set 1,
worksheet 2) and agrees with the pathway biology investigations
described in the previous section. These modules clearly reveal an
underlying heterogeneity in terms of an individual patient’s
response to infection. For example, cluster 01 defines a specific
type I IFN sub-network (and we note that the type II IFN
responsive gene CXCL10 is a member of this network, suggesting
redundant cross-talk between type I and II signalling). Type I IFN
signalling can in some cases be detrimental for individuals with
bacterial infection38. In individuals exhibiting cluster 01, we
cannot rule out that those patients showing a type I IFN response
may also be virally infected. Statistical association of the 12
networks with 23 clinical parameters was investigated (Fig. 6c).
Sugar levels were associated with clusters 01 and 06. The
association with cluster 01 is not obvious and may be indicative of
STAT regulation of glycolysis, whereas cluster 06 consists of
members associated with glycerol uptake and metabolism. The
most common association was with neutrophils and clusters 01,
05, 06, 11 and 12, whereas none of the clusters are associated with
gestational age. It should be considered that the overall sample
size for these associations is small and will require further
validation studies.
The inter-patient variability of the modules is both qualitatively
and quantitatively high and severely limits their use for a host-
directed infection signal. Further heterogeneity is observed in
inter-patient responses for immune cell compartments (Fig. 6d).
For instance, although most sepsis cases show high levels of
neutrophil markers, a small subset have levels commensurate
with neutropenia. Thus, an examination of the cellular
compartments is also insufficiently uniform. By contrast, the
52-gene dual-network identified using statistical and pathway
information alone (Fig. 2a) is uniformly representative of a
patient-invariant infection response. Moreover, there are no
significant confounding associations with any of the 23 clinical
parameters tested for the 52-gene dual-network.
52-Gene dual-network accurately predicts neonatal infection.
To test whether the 52-gene dual-network has predictive value,
we applied four distinct machine-learning algorithms: random
forest, support vector machine, k-nearest neighbour and receiver
operator characteristics (ROC) for classification. Algorithm
performance was assessed, with respect to node performance,
by estimating the generalization error (measuring how well a
learning-algorithm performs in new and unseen data) using a
replicated leave-one-out cross-validation (LOOCV) approach.
We replicated the cross-validation algorithm 100 times averaging
out any variation in error estimates resulting from randomness
while splitting the data set into training and test sets at each step.
Figure 7a shows the average LOOCV error rate over 100 repli-
cations as a performance measure with biomarkers listed
sequentially. When the number of genes included was 19 or more
the error rate was consistently 0% for all four machine-learning
methods, thus confirming internal consistency of the selected
markers as a classifier. Pleasingly, this number of genes is in
excellent agreement with the computed optimal number of bio-
markers (n¼ 24) from our previous in silico simulation studies19.
For all subsequent testing, we proceeded with the ROC-based
classifier39, as this does not require any tuning of parameters and
simplifies classification to a univariate decision that can easily be
applied to independent data. An analysis of the individual
pathways using the ROC-based classifier provided an accuracy of
84% for innate markers, 65% for the adaptive markers and 74%
with the metabolic markers; whereas all three pathway markers
combined gave an enhanced accuracy of 98% (sensitivity¼ 100%,
specificity¼ 97%). Hence, combination of the three pathways
provides an optimally robust classifier.
Next, replication and validation of the classifier on different
microarray platforms and patient samples that were not part of
the original gene selection process was performed (Fig. 7b and
Supplementary Fig. 11). In our platform test set, we used 42
of the training-set samples (18 infected, 24 controls) for 48
(matched) genes with a completely different microarray platform.
A ROC classifier when applied to this platform correctly assigned
100% of samples to control or bacterially infected groups
(sensitivity¼ 100%, specificity¼ 100%).
In our validation test set, we used a completely new
independent set of 26 samples (16 infected and 10 controls) that
were analysed on three different microarray platforms. ROC
classification based on the training set when applied to the new
validation test set correctly assigned 100% of samples to control
or bacterially infected groups with sensitivity¼ 100% and a
specificity¼ 100% (Supplementary Dataset 3). Notably, a further
three virally infected samples classified as control and align with
control samples in hierarchical clustering (Fig. 7c). These results
are in agreement with the CMV-infected case shown in Fig. 1 that
is also not recognized by the dual-network and also clustered with
the controls and not bacterially infected samples.
We compared the outcome of the 52-gene dual-network with
recently published host protein biomarkers (CD69 and FCGR1A)
of neonatal sepsis that have been reported to have 100%
sensitivity and 22–44% specificity16. It is worth noting that
FCGR1A is a member of the dual-network classifier. For this
purpose, we tested whether expression levels of CD69 and
FCGR1A (CD64) would sufficiently predict infection on the
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training set. We trained the ROC-based classifier on these two
genes with the 62-sample training set and used LOOCV to assess
its accuracy within the same set. The LOOCV analysis of these
markers at the RNA level developed 74% sensitivity with 91%
specificity with an overall accuracy of 84%. Although these results
show the potential use of these markers, they clearly exhibit
sensitivity values less than specificity and have reduced accuracy
in comparison with the 52-gene dual-network classifier that is
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more robust against sample-to-sample variation of individual
genes.
The most pressing clinical need is to identify bacterial infection
in individuals that are suspected to have infection at the first time
of symptoms developing, who subsequently have negative
bacterial cultures. To investigate this, we selected a completely
new group of 30 patients who were suspected of being infected at
the time of sample collection but who had blood culture-negative
test results. The 52-gene ROC classifier applied to this suspected
infected test set assigned 17 of the 30 patient samples to the
bacterially infected group (Fig. 7d). Subsequent expert assessment
based on clinical criteria indicated 6 infected and 15 non-infected
samples (Fig. 7d top) with 9 samples where a clinical
categorization could not be confidently made (Fig. 7d bottom
left). Concordance between classifier prediction and expert
opinion for the infected and non-infected was moderate (Cohen’s
kappa k¼ 0.24, in relation to the empirically achievable k¼ 0.46;
Fig. 7d middle) and comparison of classifier predicted infection
with expert assessment showed good agreement with statistically
significant differences in days on antibiotics and neutrophil count
between classified control and infected suspected samples
(Fig. 7e). For comparison, the predictions of the CD69þ
FCGR1A are shown in Fig. 7d top and bottom, and exhibits a
very low concordance based on Cohen’s kappa test for the CD69/
FCGR1A classifier versus expert assessment of k¼ 0.05 out of an
empirically possible k¼ 0.40. In addition, using the Expert
opinion as ‘gold-standard’, Fig. 7d bottom right shows the much
reduced accuracy values for CD69/FCGR1A in contrast to the 52-
gene classifier. These findings highlight the difficulty faced by
clinicians in determining cases of blood culture-negative sepsis
and strongly support the future clinical utility of the 52-gene
classifier. We conclude that the 52-gene dual-network has
excellent efficacy for predicting bacterial infection.
52-Gene dual-network is robust against gestational age. In
considering the demographic data, it is evident that there is a
difference in mean corrected gestational age of infected and
controls. Hence, it is important to be sure that gene expression
levels of the 52-genes are not a reflection of differing maturity of
the immune system. We therefore examined our classifier gene
set by looking at gene expression within groups according to
gestational age. Notably, we find there is no statistical difference
in gene expression of the 52-gene dual-network between infants
of differing gestational ages (Supplementary Table 2). Therefore,
in this study group, the dual-network trait is robust against
variation across gestational ages. It is also noteworthy that
although a statistically significant increase in neutrophils is
detected (Fig. 3d), the dual-network is reliable in stratifying
infected infants who had neutropenia and also fails to detect viral-
infected cases.
To test for a dependence on gestational age for any of the 824
genes altered in sepsis, we applied a linear model to the sepsis
samples of the training set for each gene by regressing the
gestational age as a continuous variable. No statistically
significant age-dependent effects were found after false discovery
rate correction. Hence, any confounding issue with gestational
age is statistically non-discernable for sepsis cases. As this analysis
does not rule out nonlinear association, we repeated this analysis
with cubic and quadratic regressive fits for gestational age, and
found no significant associations. Thus, although we cannot
absolutely rule out a confounding factor associated with
gestational age, our analysis indicates that the alterations in
sepsis cases is due to host immune response to infection.
Discussion
Here, we report the underlying in vivo molecular phenotype of
microbiologically confirmed neonatal sepsis. Strikingly, we find a
highly exacerbated and unbalanced homeostatic systemic innate
immune and metabolic response, which is accompanied by a
reduced lymphoid involvement. The strength and magnitude of
these changes show the remarkable ability of the neonate to
recognize and acutely mount a vigorous but highly focused
response. The response is not a ‘storm’ but instead exhibits an
altered set-point in the regulatory communication between innate
and adaptive immune cells. At the patient level, an individualized
assortment of functionally related modules of expressed genes is
present. Despite this heterogeneity, a more consistent response of
a 52-gene dual-network consisting of three pathways, innate,
metabolic and adaptive immune pathways, is developed and can
identify with high accuracy bacterially infected, but not in virally
infected, cases examined. It is noteworthy that necrotizing
enterocolitis samples classified positive for infection
(Supplementary Data set 3), supporting the case for a high level
of specificity in the molecular systemic response to infection. For
future translational work, more sensitive and specific results
would enable empirical antibiotics to be avoided in all but the
most critically ill newborns. This is critically important given
concerns that empirical antibiotics may increase the risks of
developing necrotizing enterocolitis and mortality in premature
infants40.
The scale of changes detected in neonates is vastly different
from those recorded in adults, although at an individual gene or
protein analytic level some of our findings are consistent with
those of studies carried out in older populations41. Elevated TLRs
have been observed in adult pre-sepsis42 and in children with
septic shock43. Downregulation of T-cell signalling, antigen
processing and reduced HLA II expression43–46 has also been
described previously in adult and paediatric sepsis and in fetal
inflammatory response syndrome10. However, there are also clear
differences, for instance, IFNg -IL12 axis, while detectable is not
Figure 6 | Network analysis of patient-specific response to infection. (a) Patient-specific expression profiles. Networks of 824 statistically differentially
expressed probes (using eBayes with Benjamini–Hochberg correction adj.Pr0.01, fold change Z2) visualized using BioLayout Express 3D. Three groups of
genes are identified, which correspond to those identified by hierarchical clustering in Fig. 1b. Co-expressed genes within networks were then defined with a
Pearson correlation r¼0.78 and by applying a Markov clustering (MCL) inflation value of 4 and pre-inflation value of 3 and are shown as coloured clusters (for
example, Cluster 01 and so on). (b) Twelve MCL clusters of genes are displayed for bacterial infected patients to show patient-specific responses. Average
expression values of MCL clusters were calculated from per gene normalized against mean of control samples and ordered by Euclidean distance. Full
expression profiles of these clusters can be seen in Supplementary Fig. 6. (c) Twelve gene expression clusters showing heterogeneity within the group of
infected neonates were tested for association with clinical parameters. For each infected neonate and cluster, median gene expression was calculated and tested
for statistical association with each of the clinical parameters (see Supplementary Data set 4). Wilcoxon rank sum tests were used to test association with
binary clinical parameters, Spearman rank correlation tests were used to test association with continuous clinical parameters (sugar, neutrophil count, postnatal
age, platelets, duration on antibiotics, pH, white cell count (WCC), hemoglobin (Hb), gestational age). The colour scale represents the P value estimate and
asterisks identify Wilcoxon rank sum or Spearman rank correlation significant test outcome at Pr0.05. (d) Cell type enrichment analysis performed at an
individual patient level shows patient-specific responses. Median signal levels for cell type-specific gene lists as detailed in Supplementary Data set 2 are plotted
(±median absolute deviation) for B, T, NK cells, neutrophil, monocyte and dendritic cells. Control, blue; bacterial infected, red.
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differentially activated as observed in older population groups11
and agrees with previous studies on the role of IL12 in neonatal
sepsis47. Also notable are elevated levels of myeloid-derived
suppressor cell markers that may affect the set point in the
regulatory cross talk with the lymphoid compartment. Other key
homeostatic regulatory mediators include FFAR2 that is regulated
by short-chain fatty acids derived from the gut microbiota that
mediate an anti-inflammatory role in immune cell function as
well as lipid energy metabolism. Altogether, these responses
support the notion of alterations in the homeostatic control
mediated by the regulatory interplay between the microbiota,
innate and adaptive immunity24. The set point for immune
control is extended to the regulation in co-stimulatory signalling
between antigen-presenting cell and T cells, and in neonatal
sepsis we, find a highly focused inhibitory co-stimulatory
response mediated through marked upregulation of, especially,
CD85 receptors that have inhibitory functions. Concomitantly, a
broad array of cell intrinsic immune repressors are also
significantly upregulated, including IL1R2, ILRN, A20, IkBa,
(NFKB1A) TOLLIP, IRAKM, TRAIL-R3, TRAFD1, SOCS1 and
SOCS3. These observations provide new insight into the
homeostatic control mechanisms involved in governing the
immune response in sepsis. The immune homeostatic set point
mechanistically determines the level at which the innate immune
system activates the adaptive response. Thus, in neonatal sepsis,
we propose that a heightened homeostatic set point culminates in
a regulatory suppressed response.
Methods
Patient recruitment and power calculations. The study was conducted in the
Neonatal Unit, Royal Infirmary of Edinburgh, and the Division of Pathway
Medicine, University of Edinburgh. Infants having blood cultures taken to inves-
tigate suspected infection (Supplementary Table 3b) and ‘well’ control infants
having blood taken for other clinical reasons (Supplementary Table 3c) were
studied. A more extensive list of clinical criteria assessed for all samples used in the
study are provided in Supplementary Data set 4. Five infants had samples included
from more than one episode of infection. After parent consent, we obtained blood
samples at the time of first clinical signs of suspected infection with an additional
0  5–1ml of whole blood for expression profiling collected alongside the ‘gold-
standard’ microbiological blood culture. Samples taken from patients with sus-
pected clinical infection that proved to have microbiological evidence of infection
from a usually sterile body site were identified and formed the infected group. Full
clinical assessment for early and late symptoms and signs of sepsis followed criteria
for neonatal sepsis taken from data as detailed in Supplementary Data set 4, with
the blood culture test used as the ‘gold standard’ for diagnosis of sepsis. For patient
samples with coagulase-negative staphylococcus full clinical assessment was con-
ducted independently by two clinicians (CLS and BJS/JO) and clinical evidence
supporting or refuting inclusion was reviewed. The neonatal unit uses the defini-
tions of the Vermont Oxford Network for infection surveillance48 and associated
clinical deterioration, repeat isolates and deranged blood counts were also
examined. Samples were only included as positive if both clinicians agreed that
infection was present. This was conducted blind to the results of any RNA
expression profile data. For power calculations, samples were obtained from
30 infants at 9 months of age, before vaccination. To meet with laboratory
regulations, samples that could be considered ‘high risk’ were excluded. Infants
were not included in the study if the mother was known to be positive for hepatitis
B, HIV or hepatitis C viruses. In cases where the mother was known to have a
history of drug misuse and had not had antenatal screening for blood-borne
viruses, the infants were also excluded. Other exclusion criteria were infants who
did not require clinical blood samples and infants for whom extra blood sampling
might be of particular risk, for example, infants with an underlying disorder
causing anaemia.
For RNA isolation, blood was immediately injected into a PAXgene blood RNA
tube. Frozen samples were subjected to RNA extraction and microarray analysis
performed. Before embarking on this study, we performed a power calculation
using the Illumina chip platform, on an independent set of 30 infant samples
(Supplementary Fig. 8). This shows that the study design has 90% power to detect
a twofold change in expression with an a of 1% (false discovery rate (FDR)
corrected), for more than 99% of 35,177 gene probes present on the array. RNA
was extracted using a protocol validated for use in small volume neonatal blood
samples18.
Patient sample analysis workflow and study design. The patient demographics,
microbial organisms isolated and reasons for blood sampling in controls for all
patient sets are shown in Supplementary Table 3. All samples were processed for
genome-wide transcriptional analysis using microarrays. On the basis of power
calculations (Supplementary Fig. 8), sample size of approximately 25 for each
group has Z90% power to detect twofold changes in expression level of 99% of
probes on the microarray. A schematic of patient recruitment and sample pro-
cessing workflow for the 285 samples processed for the main study and validation
arm is shown in Supplementary Fig. 9. For the computational and statistical
pathway biology aspects of this study, a summary of data analysis workflow and
associated figures are provided in Supplementary Fig. 10. The main study arm
primarily used RNA profiling data using the Illumina HT12 platform from
27 patient samples with a confirmed blood culture-positive test for sepsis (bacterial
infected cases), 1 cytomegalovirus (CMV)-infected case and 35 matched controls.
Samples from these cases (not including the viral infected case) are referred to as
the ‘training set’ in this study. For assessing reproducibility with a different assay
platform, we examined a subset of 42 of these samples using the CodeLink gene
expression platform (comprising 18 bacterial infected and 24 control samples)
named in this study as ‘platform test set’. Subsequently, for independent clinical
evaluation, the 52-gene set classifier was applied to a further 29 new and inde-
pendent samples (comprising 16 bacterial infected, 3 viral infected and 10 control
samples) named in this study as ‘validation test set’. CodeLink data used in the
platform and validation test sets developed a variable but acceptable maximal
density for approximately 50% of chips analysed. Finally, a set of 30 new samples
collected upon suspicion of infection but with negative blood culture were
analysed, named in this study as ‘suspected infected test set’. A detailed summary of
the workflow for the training and testing of the 52-gene set classifier of sepsis in
neonates is shown in Supplementary Fig. 11.
Figure 7 | Validation of the 52-gene dual-network classifier. (a) Members of the network as a classifier of neonatal infection using leave-one-out cross-
validation analysis using four independent machine-learning algorithms (red circle, random forest; green triangle, support vector machines; blueþ ,
K nearest neighbour and black x, receiver operator characteristics). (b) Flow chart of biomarker classifier validation. Flow chart showing the samples used
for classifier generation and the validation results. (c) Heat map showing hierarchical clustering of 18 infant samples (9 bacterially infected, 6 control,
3 virally infected) based on the 50 probes that were in common between the classifier gene set and the Affymetrix U219 platform. Hierarchical clustering
was based on Euclidean distance. Control, blue; bacterial infected, red; viral infected, black. Classification of bacterial infection is indicated (0¼ non-
infected, 1¼ infected). (d) Comparison of microarray-based classifier and expert assessment for classification of samples from patients with suspected
infection. (Top) Comparison of expert assessment, CD69/FCGR1A and the 52-gene classifier on samples scored ‘high’ and ‘low’ likelihood of infection
by expert assessment. (Middle) 52-gene classifier prediction and expert assessment of suspected sepsis cases (red¼ concordance of ‘infection’,
blue¼ concordance of ‘control’, dark grey¼discordance of microarray classifier and expert assessment). (Bottom left) Comparison of CD69/FCGR1A and
52-gene classifier of samples scored ‘medium’ likelihood of infection by expert assessment. Classification of bacterial infection is indicated (0¼ non-
infected (pale blue), 1¼ infected (pink)). (Bottom right) Sensitivity, specificity and accuracy of CD69/FCGR1A and the 52-gene classifier against expert
classification for suspected samples from d top. A heat map showing the 30 infant samples of suspected infection based on the 46 probes that were in
common between the classifier gene set and the CodeLink platform is shown in Supplementary Fig. 7. (e) Bar plots showing clinical criteria in suspected
infection cases as judged by the 52-gene classifier and expert assessment. Days on antibiotics and neutrophil counts are shown for samples based on
classification of control (pale blue) and bacterial infection (pink) showing median and standard error of the median. Days on antibiotics, classifier
prediction: infected: n¼ 15 (excluding 2 missing values); control: n¼ 12 (excluding 1 missing value). Days on antibiotics, expert assessment: infected: n¼ 5
(excluding 1 missing value); control: n¼ 14 (excluding 1 missing value). Neutrophil count, classifier prediction: infected, n¼ 17; control, n¼ 13. Neutrophil
count, expert assessment: infected: n¼6; control: n¼ 15.
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Statistical analysis. High-quality RNA from infected and control infants was
hybridized onto Illumina Human Whole-Genome Expression BeadChip HT12v3
microarrays comprising 48,802 features (human gene probes). Microarray quality
analysis used the arrayQualityMetrics package in Bioconductor49 and a gender
check was performed using Y-chromosome-specific loci. Using the ‘lumi’
Bioconductor package, raw data from 63 samples were transformed using a
variance stabilizing transformation before robust spline normalization to remove
systematic between-sample variation. Microarray features that were not detected,
using detectionCall on any of the arrays, were removed from analysis and the
remaining 23,342 features were used for subsequent statistical analysis. Data were
statistically examined to assess gestational age as a confounding factor. Within each
sample group (control, infected), samples were age classified into bins based on the
33 and 66% corrected gestational age quantile values, yielding three age groupings.
Comparison of normalized data between groups utilized linear modelling of the
log2 scale expression values between groups and subsequent empirical Bayesian
approaches to moderate the test statistic by pooling variance information from
multiple genes. This included vertical P-value adjustment for multiple testing
(Benjamini–Hochberg) to control for false discovery rate using the Bioconductor
package ‘limma’50. Statistically significant differentially expressed genes were
examined further: heat maps and line graphs with hierarchical clustering by
Euclidean distance were examined using Partek Genomics Suite v6  5, and
visualization of networks of genes looking for patient-specific responses using
BioLayout Express 3D37. Unsupervised clustering of patient samples was carried
out: probes with coefficient of variation greater than 0.1 were used (10,206) and
hierarchical clustering was based on Euclidean distance.
For purposes of classification, we refer to the 62 Illumina-hybridized samples
with the selected subset of 52 genes as ‘training set’. We employ multiple types of
classification test sets, which are defined as follows (Supplementary Fig. 9). In
addition to the Illumina microarray analysis, we examined a subset of 42 of these
samples (18 infected, 24 controls) using CodeLink Whole Human Genome arrays,
referred to as ‘platform test set’. Subsequently, the classifier was applied to a further
26 new and independent samples (16 bacterially infected samples from 15 infants
and 10 control samples), which were run on CodeLink (7 infected and 3 control),
Affymetrix HG-U133 (two infected, three control) or Affymetrix Human Genome
U219 (9 infected and 6 control) arrays. These are collectively referred to as
‘validation test set’. We also assess the performance of our classifier on
30 independent samples with suspected but initially unconfirmed infection
(CodeLink arrays) and refer to this as ‘suspected infected test set’.
Use of the term ‘classifier’ refers to the classification algorithm and its trained
state based on our set of 52 biomarkers. In discussion of the set of 52 biomarkers
themselves, we refer to these as ‘classifier gene set’ or ‘52-gene classifier’. before
training and testing the ROC-based classifier on the training and test sets, the
original log2 expression values for the 52-gene set were scaled to mean¼ 0 and
standard deviation¼ 1 (that is, z-transformation per sample). The data scaling
allows for prediction of biological samples on a separate microarray platform from
that used in training the classifier. This ROC-based classification algorithm does
not require any parameter optimization or tuning because its only parameter is the
number of predictor genes to be used, which is in this case pre-determined as the
number of genes suggested as predictors through prior analysis. The same scaling
procedure (independently applied to this small subset of genes) was used to test a
previously published gene set (CD69, FCGR1A) for performance on our training
set of 62 Illumina microarray samples.
Network and pathway analysis. Computational network-based approaches were
used to examine relationships in the data using correlation of gene expression and
biological relationships. IPA (http://www.ingenuity.com), DAVID51 and a
manually curated data set of human gene interactions in InnateDB (http://
www.innatedb.com)22 were used to examine biological network relationships and
association with known pathways, for example, Kyoto Encyclopedia of Genes and
Genomes52. The InnateDB network was analysed using Cytoscape 2.6.3 (ref. 53)
and the cytoHubba plugin54 to investigate a variety of properties of a network
including the identification of network hubs and bottlenecks, which may represent
the key regulatory nodes in the network. The network was also analysed to identify
‘active sub-networks’ using the jActiveModules23 plugin to identify densely
connected differentially expressed sub-networks. Cellular localizations of network
components were visualized using cytoscape and the Cerebral v.2 (ref. 55) plugin.
The contribution of specific blood cell subsets was examined by categorizing
responses according to cell type using cell-specific gene markers described by
Abbas and colleagues21. Pathway analyses were carried out step-wise using a
pathway biology approach, becoming more focused until a defined sub-network of
52 differentially expressed genes was identified. The selected genes had adjusted P
values of r10 5, fold changes of Z4 and were highly connected in terms of
biological pathways and networks.
Classifier analysis. These 52 genes were then assessed for prediction precision in
a LOOCV error modelling using four different classification methods: random
forests, support vector machines, K nearest neighbour and ROC-based classifica-
tion. LOOCV was repeated 100 times for each set of selected genes following a
random ordering of the data at each replication to minimize variability of the error
estimates. For independent technical validation of RNA expression levels of the
classifier gene set outside the neonatal sample set used for feature selection, a subset
of samples run on CodeLink Human Whole-Genome microarrays was examined
(platform test set). The subset was chosen only by virtue of being previously run on
CodeLink. ROC classification39 was used to repeat the internal cross-validation on
this subset using the markers that were present on both arrays and then using the
trained classifier to predict the CodeLink samples. For further validation, a new
sample set of 16 bacterially infected and 10 control samples (not previously used
for feature selection or other analyses, but obtained in the same study setting with
the same sample collection protocol) run on CodeLink, Affymetrix Human
Genome HG-U133 Plus 2  0 or Affymetrix Human Genome U219 arrays had the
ROC-based classifier applied (validation test set). All classification analyses were
performed with R56, classification error in relation to gene set size was performed
with the R package ‘optBiomarker’19 and ROC-based classification uses the R
package ‘rocc’39.
Study approval. Written informed consent was obtained from parents of all
enrolled infants in accordance with approval granted by the Lothian Research
Ethics Committee for blood samples for RNA isolation obtained at the first time of
clinical signs of suspected sepsis (reference 05/s1103/3). Samples used in power
calculations were collected with the approval of the Gambia Government/MRC
Laboratories Joint Ethics Committee and London School of Tropical Medicine
ethics committee (reference SCC1085, L2008.63).
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